The DOI matches its Crossref record; 38 of the 40 references it cites were found in a registry or an index.
LATS1 K751 acetylation blocks activation of Hippo signalling and switches LATS1 from a tumor suppressor to an oncoprotein
Abstract
Large tumor suppressor 1 (LATS1) is the key kinase controlling activation of Hippo signalling pathway. Post-translational modifications of LATS1 modulate its kinase activity. However, detailed mechanism underlying LATS1 stability and activation remains elusive. Here we report that LATS1 is acetylated by acetyltransferase CBP at K751 and is deacetylated by deacetylases SIRT3 and SIRT4. Acetylation at K751 stabilized LATS1 by decreasing LATS1 ubiquitination and inhibited LATS1 activation by reducing its phosphorylation. Mechanistically, LATS1 acetylation resulted in inhibition of YAP phosphorylation and degradation, leading to increased YAP nucleus translocation and promoted target gene expression. Functionally, LATS1-K751Q, the acetylation mimic mutant potentiated lung cancer cell migration, invasion and tumor growth, whereas LATS1-K751R, the acetylation deficient mutant inhibited these functions. Taken together, we demonstrated a previously unidentified post-translational modification of LATS1 that converts LATS1 from a tumor suppressor to a tumor promoter by suppression of Hippo signalling through acetylation of LATS1.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, LATS1 requires phosphorylation to be active [105] and LATS1 phosphorylation was increased on the non-acetylated, less stable LATS1K751R [104].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [104]
In the citing paper
“This mechanism seemingly relies on its difference in deacetylases, LATS1 by SIRT3/4 [104] and MOB1 by HDAC6 [107], to fine tune Hippo/YAP signaling and modulate its function as both a tumor suppressor and tumor driver, again highlighting the issues of using pan KAT/KDAC inhibitors to probe these biological questions.”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [104]
In the citing paper
“The stabilization of LATS1K751Q therefore results in increased YAP in the nuclear fraction and a subsequent increase in lung cancer growth and migration when expressed in xenograft mouse models [104].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [104]
In the citing paper
“LATS1K751Q thus decreases LATS1 phosphorylation and phosphorylation of its downstream target YAP (Figure 5) [104].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [104]
In the citing paper
“Acetylation of K751 by CBP results in an extended LATS1 half-life and decreased LATS1 ubiquitination (Figure 5) [104].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [104]
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Ferroptosis as a p53-mediated activity during tumour suppression
Jiang, L., Kon, N., Li, T., Wang, S.-J., Su, T., Hibshoosh, H., Baer, R., & Gu, W. (2015) · Nature · doi:10.1038/nature14344 · Cited by 3,398
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092
TEAD mediates YAP-dependent gene induction and growth control
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C.-Y., Chinnaiyan, A. M., et al. (2008) · Genes & Development · doi:10.1101/gad.1664408 · Cited by 2,498
Hippo pathway in organ size control, tissue homeostasis, and cancer
Yu, F.-X., Zhao, B., & Guan, K.-L. (2015) · Cell · doi:10.1016/j.cell.2015.10.044 · Cited by 2,206
Huang, J., Wu, S., Barrera, J., Matthews, K., & Pan, D. (2005) · Cell · doi:10.1016/j.cell.2005.06.007 · Cited by 1,863
Mechanisms of Hippo pathway regulation
Meng, Z., Moroishi, T., & Guan, K.-L. (2016) · Genes & Development · doi:10.1101/gad.274027.115 · Cited by 1,667
The Hippo pathway: regulators and regulations.
Yu, F.-X., & Guan, K.-L. (2013) · Genes & Development · doi:10.1101/gad.210773.112 · Cited by 1,231
The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal
Zhao, B., Tumaneng, K., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2303 · Cited by 1,205
The Hippo–YAP pathway in organ size control and tumorigenesis: an updated version
Zhao, B., Li, L., Lei, Q., & Guan, K.-L. (2010) · Genes & Development · doi:10.1101/gad.1909210 · Cited by 1,144
Cited by
Oxidative stress–CBP axis modulates MOB1 acetylation and activates the Hippo signaling pathway
Jin, J., Zhang, L., Li, X., Xu, W., Yang, S., Song, J., Zhang, W., Zhan, J., Luo, J., & Zhang, H. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac189 · Cited by 99
“A series of studies have also confirmed that MST1 (27), LATS1 (28) and YAP (29) can be acetylated, and all of them have a significant impact on the molecular functions and activation of the Hippo signaling pathway.”
Self-citationRole Of YAP Signaling in Regulation of Programmed Cell Death and Drug Resistance in Cancer
Zhou, W., Lim, A., Edderkaoui, M., Osipov, A., Wu, H., Wang, Q., & Pandol, S. J. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.83586 · Cited by 52
“Acetylation of LAST1 inhibits YAP phosphorylation and degradation and promotes cancer cell invasion and growth [63].”
BackgroundTargeting Hippo signaling in cancer: novel perspectives and therapeutic potential
Lv, L., & Zhou, X. (2023) · MedComm · doi:10.1002/mco2.375 · Cited by 58
Zhang, Y. X., Tan, Y., Yuan, J., Tang, H., Zhang, H., Tang, Y., Xie, Y., Wu, L., Xie, J., Xiao, X., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216907 · Cited by 42
Self-citationAcetylation: a new target for protein degradation in cancer
Crawford, C. E. W., & Burslem, G. M. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2025.01.013 · Cited by 20
Metadata
- Authors
- Yang, S., Xu, W., Liu, C., Jin, J., Li, X., Jiang, Y., Zhang, L., Meng, X., Zhan, J., & Zhang, H.
- Affiliations
- Peking University (CN)
- Tsinghua University (CN)
- Corresponding author
- Zhang, Hongquan
- ORCID
- Venue
- Science China Life Sciences
- Published
- 2021-04-29
- Volume
- 65
- Issue
- 1
- Pages
- 129-141
- ISSN
- 1674-7305 (ISSN-L)
- 1869-1889
- OpenAlex
- W3157197229
- Cited by
- 24
- References
- 40
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 5 · 2023: 7 · 2022: 2 · 2021: 1
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Science China Life Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Keywords
- LATS1, Hippo signaling pathway, CBP, SIRT3, SIRT4, protein acetylation, protein stability, ubiquitination, YAP phosphorylation, YAP nuclear translocation, lung cancer, cell migration and invasion, post-translational modification
- MeSH terms
- Adenocarcinoma of Lung, Hippo Signaling Pathway, Acetylation, Acetyltransferases, Animals, Cell Movement, Male, Mice, Inbred BALB C, Mice, Nude, Oncogene Proteins, Protein Serine-Threonine Kinases, Tumor Suppressor Proteins, Mice, Ubiquitination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: LATS1 K751 acetylation blocks activation of Hippo signalling and switches LATS1 from a tumor suppressor to an oncoprotein. https://app.cochat.ai/papers/10.1007/s11427-020-1914-3
- The paper
- Yang, S., Xu, W., Liu, C., Jin, J., Li, X., Jiang, Y., Zhang, L., Meng, X., Zhan, J., & Zhang, H. (2022). LATS1 K751 acetylation blocks activation of Hippo signalling and switches LATS1 from a tumor suppressor to an oncoprotein. Science China Life Sciences. https://doi.org/10.1007/s11427-020-1914-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.